Clicky

Cannabis

CBG benefits evidence

October 12, 2026
13 Min Read

By HealthDataConsortium.org Research Team

CBG (cannabigerol) is a cannabis-plant compound described in research as nonintoxicating. Its acid form, CBGA, is the chemical starting point the plant uses to make THC and CBD, which is where the nickname “mother of all cannabinoids” comes from. The nickname makes CBG sound powerful. Human research is much smaller than the hype.

Here is what early human studies show, based on the sources we could check as of October 12, 2026:

  • Anxiety and stress: In one small trial of healthy adults, self-rated anxiety dropped slightly more after a single 20 mg dose of CBG than after a placebo. The gap was small, and a standard anxiety questionnaire did not confirm it.
  • Sleep: A four-week trial in veterans with sleep problems found no statistically significant difference between CBG and placebo.
  • Short-term tolerability: Single-dose studies in healthy adults suggest CBG is tolerated well over short periods. They also show that meals affect how much CBG reaches the blood.
  • Disease treatment: We found no published controlled human trial showing that CBG treats any disease.

Pilot and short-term studies are a starting point. They do not validate a store-bought product or long-term use, and the sections below explain why.

Evidence Worksheet: What Each Human Study Can and Cannot Tell You

Each entry uses the same five checks: the observed context (who was studied and what happened), the source type, the evidence limit, the question still unresolved, and a next-step prompt you can borrow.

Single 20 mg dose for anxiety, stress, and mood (Scientific Reports, 2024)

  • Observed context: 34 healthy adults aged 21 to 60 in Washington State, all with cannabis experience (about two-thirds had never used CBG), took one 20 mg dose of a hemp-derived CBG tincture. A week apart, they took a placebo instead, without knowing which was which. On a 0 to 10 scale, anxiety ratings fell by about 0.95 points after CBG and about 0.66 after placebo, starting from a low average near 3.6. So most of the improvement happened on placebo too, and the difference between them was about a third of a point. Stress ratings were lower after CBG at the first check-in, roughly 20 minutes after dosing, but not later. Mood ratings did not differ. A standard anxiety questionnaire showed no significant difference at any single time point. On a word-recall test, people remembered about half a word more on the second learning round and one word more on the third; the statistical result sat right at the usual cutoff (p = 0.050). Participants reported no intoxication, and the impairment tests showed none.
  • Source type: Double-blind, placebo-controlled crossover trial, run remotely over video call and registered in advance on ClinicalTrials.gov.
  • Evidence limit: One modest dose, with effects checked only 20 to 60 minutes later. No vital signs or physical exams, and a non-clinical group of experienced cannabis users. The researchers ran many comparisons without adjusting for multiple testing, so some results could be due to chance. They called the lack of effect on the standard questionnaire a reason for caution and said replication is needed. A company that works with CBG funded the study, and one author founded that company. The paper states the funder had no role in the analysis or interpretation.
  • Unresolved question: Would the effect appear in people diagnosed with anxiety disorders, in people who have never used cannabis, or with daily use over weeks?
  • Next-step prompt: When a product cites “clinical research” for calm, ask whether it was one dose in healthy volunteers, how big the gap from placebo was, and whether anyone has repeated it.

CBG for sleep in veterans (Medical Cannabis and Cannabinoids)

  • Observed context: 63 veterans in California with self-reported sleep problems were randomly assigned to CBG (33 people) or placebo (30). After a two-week lead-in, the CBG group took 25 mg a day for two weeks, then 50 mg a day for two more. Sleep scores improved in both groups, with no statistically significant difference. Quality-of-life and PTSD symptom scores followed the same pattern. The authors described CBG as well tolerated.
  • Source type: Fully remote, randomized, triple-blind, placebo-controlled trial (registered as NCT05088018).
  • Evidence limit: Only 35 of the 63 people finished without major protocol deviations (18 on CBG, 17 on placebo), and treatment lasted four weeks. The authors wrote that no firm conclusion can be drawn about CBG improving sleep.
  • Unresolved question: Would a larger or longer trial, or a different dose, separate CBG from placebo at all?
  • Next-step prompt: When both groups improve, placebo is doing real work. Ask how much better the active group did than the placebo group, not just whether people felt better. Our guide to the placebo effect in clinical trials explains why.

How the body absorbs CBG, and short-term safety (Cannabis and Cannabinoid Research, 2024; Journal of Pharmacology and Experimental Therapeutics, 2026)

  • Observed context: A 2024 pilot study gave adults a single 25 mg dose of CBG with either a low-fat or a high-fat meal, in two oral forms (plain isolate or an emulsified version). The high-fat meal produced higher peak and total blood CBG levels, and the meal mattered more than the emulsified form. A 2026 placebo-controlled study gave healthy adults single doses from 25 to 200 mg. Its abstract reports a favorable safety and tolerability profile and mostly minimal subjective effects. At 50 mg, people rated themselves less “jittery” and less “active”; at 100 mg, less “calm”; and at 200 mg, hungrier. That is not a simple calming pattern.
  • Source type: A human pharmacokinetic pilot study (how the body absorbs a substance) and a single-ascending-dose safety study.
  • Evidence limit: Both used single doses in healthy people and measured blood levels or short-term effects. Neither tested whether CBG helps any condition.
  • Unresolved question: What happens with daily dosing, in older adults, in people with health conditions, or alongside other medicines?
  • Next-step prompt: The milligram number on a label does not tell you how much reaches your bloodstream. Our guide to CBD oil, gummies, and capsules explains why that matters when comparing products, and the same logic applies to CBG.

Survey of 127 people who already use CBG (Cannabis and Cannabinoid Research, 2022)

  • Observed context: As summarized in the 2024 anxiety trial paper, people using CBG-dominant products most often reported using them for anxiety (51%), chronic pain (41%), depression (33%), and insomnia (31%). Most said CBG worked better than conventional medicines for those problems. A minority reported dry mouth, sleepiness, increased appetite, or dry eyes.
  • Source type: Retrospective, self-reported survey.
  • Evidence limit: There was no placebo and no comparison group; the products varied in CBG content, and answers rely on memory. The same authors said these findings need to be tested in double-blind, placebo-controlled trials.
  • Unresolved question: Which of these reported benefits survive blinded testing?
  • Next-step prompt: Treat a percentage from a user survey as a reason to run a trial, not as a trial result.

Another study type worth knowing is blends. A 2023 pilot tested a beverage powder that combined CBG with CBD and a terpene to reduce exercise-related muscle soreness. Because it combined ingredients, it cannot tell you what CBG alone does.

Which Disease Claims Remain Untested in People

Much of what you read about CBG comes from animal and laboratory research. The authors of the 2024 anxiety trial list preclinical findings including antibacterial and antifungal activity, lower blood pressure, reduced eye pressure, effects on skin cells in a psoriasis model, benefit in experimental inflammatory bowel disease, pain relief, and antidepressant-like behavior in rodents. A 2025 review of CBG and the cardiovascular system likewise describes blood-pressure-lowering effects in mice, and a 2026 review of CBG and drug-resistant epilepsy calls itself hypothesis-generating and says the evidence does not support treating CBG as a replacement for CBD in epilepsy.

In the sources we checked, we did not find a published, placebo-controlled human trial testing CBG as a treatment for any of these:

  • Inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis
  • Glaucoma or high eye pressure
  • Bacterial or fungal infections
  • Psoriasis or other skin disease
  • High blood pressure
  • Chronic pain
  • Seizure disorders
  • Depression: the anxiety trial measured a single mood rating in healthy adults, which is not a test in people with depression
  • Anxiety disorders: the one positive trial enrolled healthy adults, not people diagnosed with an anxiety disorder

Sleep problems are the one area with a placebo-controlled trial in people reporting a problem, and it found no significant difference from placebo. “Untested” does not mean “disproven.” It means the trial that would answer the question hasn’t been done, or we couldn’t find it. A product page that implies CBG treats any condition on this list is ahead of the evidence. Our guide to judging health claims and evidence shows how to spot that gap.

Why Pilot and Short-Term Studies Do Not Validate a Retail Product

  • Different product. The anxiety trial’s tincture came from a single batch with a lab certificate. A retail product may differ in CBG content, other cannabinoids, and carrier ingredients. Our guide to what a cannabis certificate of analysis can and cannot verify shows how to check what is in a batch.
  • Different dose and timing. The studies used specific doses under set conditions: one 20 mg dose, 25 to 50 mg a day for four weeks, or single doses up to 200 mg. Meals changed absorption in the 2024 pilot study.
  • Different people. Healthy volunteers screened for many conditions are not the same as older adults, people with chronic illness, or people taking several medicines.
  • Different time frame. A single dose or four weeks says nothing about months or years of daily use.
  • Who paid for it. The anxiety trial disclosed funding from a CBG company. Disclosure is a good sign, and independent replication would be better. Our guide to conflict of interest in medical research explains how to weigh funding.

Sales pages often skip these distinctions. Our review of one CBD gummy seller is about CBD, not CBG, but it shows the pattern: the seller cited more than 20,000 clinical studies on CBD oil while naming no study for the figures it showed. Ask the same question of any CBG product: which study, which dose, which people, and was it this product?

What the FDA and CDC Say

The FDA states that it has not approved cannabis for the treatment of any disease or condition. It has approved four related prescription drugs: Epidiolex, a purified form of CBD for certain seizure conditions; Marinol and Syndros, which contain synthetic THC; and Cesamet, which contains a synthetic compound with a chemical structure similar to THC. None of them is a CBG drug. The FDA also says that products that have not gone through drug review have not been evaluated for effectiveness, proper dosing, interactions with other drugs, or dangerous side effects. That describes retail CBG products.

Two limits apply. The FDA page was last updated in July 2024 and does not mention CBG by name, so it doesn’t say how any particular CBG product is classified or whether it is legal where you live. The CDC page, last reviewed in February 2024, covers cannabis generally. It notes that edible products carry a greater risk of poisoning than smoked cannabis, and it advises keeping cannabis products in a locked, childproof container out of children’s reach. In an emergency, call 911 or Poison Control at 1-800-222-1222.

Questions to Bring to a Clinician or Pharmacist

None of these studies tells you whether CBG is a reasonable choice for you. A clinician who knows your history can help with that. Useful questions:

  • Has CBG been tested in people with my condition, or only in healthy volunteers?
  • Could CBG interact with the medicines and supplements I take? Our pharmacist and prescriber conversation checklist helps you prepare a complete list.
  • Is there an established treatment for my symptoms that I should try or continue first?
  • Does the product also contain THC, and what would that change for me?
  • What signs would tell us it is not working or is causing a problem?

Do not stop or change a prescribed medicine in favor of CBG without talking to your prescriber.

Your Next Step: Read the Study Limitations First

Before you discuss CBG with a clinician, reread the evidence-limit lines above. They are the part of each study that matters most for your decision. When a new CBG study makes headlines, fill in the same five checks yourself: who was studied and what changed, what kind of study it was, what its authors say it cannot show, what remains unanswered, and what you will ask your clinician or pharmacist.

Sources

  1. Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Scientific Reports. 2024;14:16163. doi:10.1038/s41598-024-66879-0. https://www.nature.com/articles/s41598-024-66879-0
  2. Effect of Cannabigerol on Sleep and Quality of Life in Veterans: A Decentralized, Randomized, Placebo-Controlled Trial. Medical Cannabis and Cannabinoids. doi:10.1159/000549902. ClinicalTrials.gov NCT05088018. https://pmc.ncbi.nlm.nih.gov/articles/PMC12823110
  3. Story G, Lee J, Cohen G, Rani A, Doherty J, Sela DA. Impact of dietary fat and oral delivery system on cannabigerol pharmacokinetics in adults. Cannabis and Cannabinoid Research. 2024;9(6):1543-1555. doi:10.1089/can.2023.0174. https://doi.org/10.1089/can.2023.0174
  4. Safety, Pharmacodynamics, and Pharmacokinetics of Oral Cannabigerol (CBG) in Healthy Adults. Journal of Pharmacology and Experimental Therapeutics. 2026. https://www.sciencedirect.com/science/article/abs/pii/S0022356526011845
  5. Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL. Survey of patients employing cannabigerol-predominant cannabis preparations: perceived medical effects, adverse events, and withdrawal symptoms. Cannabis and Cannabinoid Research. 2022;7:706-716. doi:10.1089/can.2021.0058 (survey results as summarized in source 1)
  6. Peters EN, et al. A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS). Journal of the International Society of Sports Nutrition. 2023;20. doi:10.1080/15502783.2023.2280113 (design as summarized in source 1)
  7. Comprehensive mini-review: therapeutic potential of cannabigerol, focus on the cardiovascular system. Frontiers in Pharmacology. 2025. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1561385/full
  8. Elucidating the putative role of cannabigerol: a hypothesis-generating review of neuroinflammatory and neuroprotective mechanisms with implications for drug-resistant epilepsy. Frontiers in Pharmacology. 2026. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1755956/full
  9. U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Content current as of July 16, 2024. https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
  10. Centers for Disease Control and Prevention. Cannabis Health Effects. Last reviewed February 16, 2024. https://www.cdc.gov/cannabis/health-effects/index.html

This article is for general information only and is not medical advice. HealthDataConsortium.org is an analytical publication, not a medical practice. Talk with a qualified healthcare provider before starting, stopping, or changing any product or medicine.